2022
The Coming of Age of Preclinical Models of MDS
Liu W, Teodorescu P, Halene S, Ghiaur G. The Coming of Age of Preclinical Models of MDS. Frontiers In Oncology 2022, 12: 815037. PMID: 35372085, PMCID: PMC8966105, DOI: 10.3389/fonc.2022.815037.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTranscription factorsEpigenetic modifiersComplex molecular landscapeXenograft modelHematopoietic cellsDeletions/additionsMolecular landscapeRecurrent mutationsCell linesGenetic abnormalitiesMDS cellsXenograft murine modelChromosomal abnormalitiesCellsIneffective hematopoiesisTransgenicHematopoiesisMutationsPreclinical modelsWide spectrumMurine modelHeterogeneous groupLandscapeComing of age
2020
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
He X, Dou A, Feng S, Roman-Rivera A, Hawkins C, Lawley L, Zhang J, Wunderlich M, Mizukawa B, Halene S, Patel A, Fang J. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. Experimental Hematology 2020, 86: 21-27.e2. PMID: 32437909, PMCID: PMC7335335, DOI: 10.1016/j.exphem.2020.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell Line, TumorCyclosporineDNA-Binding ProteinsDrug Resistance, NeoplasmGene Expression Regulation, LeukemicHumansIkaros Transcription FactorLenalidomideLeukemia, Myeloid, AcuteMiceMice, Inbred NODMuscle ProteinsMyelodysplastic SyndromesNeoplasm ProteinsUp-RegulationXenograft Model Antitumor AssaysConceptsAcute myeloid leukemiaMDS/acute myeloid leukemiaMyelodysplastic syndromeT cell activationAML patient-derived xenograft modelsG protein-coupled receptor 68MDS/AML cellsPatient-derived xenograft modelsMDS/AML cell linesDegradation of IKZF1AML cell linesCell linesActivity of CaNBone marrow cellsMDS patientsPrimary bone marrow cellsHematologic malignanciesMyeloid leukemiaAML cellsLenalidomideXenograft modelDrug AdministrationSuppressive effectProsurvival pathwaysMarrow cells